Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 5 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready
Prolacta Bioscience Inc. currently has 8 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 8 distinct examiners, which indicates that no two pending matters are being reviewed by the same person. The portfolio is also distributed across 5 distinct art units, demonstrating a high degree of technical variety in the company's biotech and pharmaceutical patent filings.
LI, SUN M is the busiest examiner for the company, with 1 pending office action under review. Because the 8 pending office actions are divided among many different examiners, the company faces a fragmented prosecution environment. Practitioners must prepare for separate examiner styles across 5 distinct art units, making it difficult to apply a uniform strategy across the entire pending portfolio. This decentralized structure requires a tailored approach for each individual matter to address the specific feedback from each examiner. The lack of examiner concentration suggests that the company's innovations are being evaluated by a wide range of experts within the USPTO.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (12%) |
| §103 only | 1 (12%) |
| Double-patenting only | 1 (12%) |
| Double-patenting + other | 1 (12%) |
| Multi-statute (no §101) | 4 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LI, SUN M | 1 | 53.2% | +27.7% |
| MOSS, NATALIE M | 1 | 30.8% | +17.1% |
| MORNHINWEG, JEFFREY P | 1 | 36.3% | +32.1% |
| KOSAR, AARON J | 1 | 71.2% | +29.9% |
| HAWKINS, AMANDA SALATA | 1 | 12.0% | +45.2% |
| FIEBIG, RUSSELL G | 1 | 62.6% | +25.0% |
| OLSON, ANDREA STEFFEL | 1 | 62.3% | -11.9% |
| MILLER, DALE R | 1 | 62.4% | +17.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18261012 | SYNBIOTIC TREATMENT REGIMENS | OLSON, ANDREA STEFFEL | 96d overdue |
| 18876045 | SYSTEMS, DEVICES, AND METHODS FOR MANAGEMENT OF MILK ALLOCATION | LI, SUN M | 57d |
| 18956759 | HUMAN MILK PERMEATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME | MOSS, NATALIE M | — |
| 18406627 | PURIFIED HUMAN MILK OLIGOSACCHARIDES COMPOSITIONS | HAWKINS, AMANDA SALATA | — |
| 18552081 | METHODS OF TREATMENT FOR FAILURE TO THRIVE | FIEBIG, RUSSELL G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18876045 | SYSTEMS, DEVICES, AND METHODS FOR MANAGEMENT OF MILK ALLOCATION | LI, SUN M | 57d |
| 18956759 | HUMAN MILK PERMEATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME | MOSS, NATALIE M | — |
| 18802726 | METHODS FOR OBTAINING STERILE MILK AND COMPOSITIONS THEREOF | MORNHINWEG, JEFFREY P | — |
| 18659554 | HUMAN MILK PRODUCTS USEFUL IN PRE- AND POST-OPERATIVE CARE | KOSAR, AARON J | — |
| 18406627 | PURIFIED HUMAN MILK OLIGOSACCHARIDES COMPOSITIONS | HAWKINS, AMANDA SALATA | — |
| 18552081 | METHODS OF TREATMENT FOR FAILURE TO THRIVE | FIEBIG, RUSSELL G | — |
| 18021043 | HUMAN MILK OLIGOSACCHARIDE COMPOSITIONS FOR USE WITH BACTERIOTHERAPIES | MILLER, DALE R | — |
| Art Unit | Apps |
|---|---|
| 1655 | 2 |
| 1693 | 2 |
| 3685 | 1 |
| 1653 | 1 |
| 1793 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18876045 | SYSTEMS, DEVICES, AND METHODS FOR MANAGEMENT OF MILK ALLOCATION | LI, SUN M | 3685 | §101 | Final Rejection | 57d | Pending | Dec 17, 2024 |
| 18956759 | HUMAN MILK PERMEATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME | MOSS, NATALIE M | 1653 | §103§112 | Non-Final OA | — | Pending | Nov 22, 2024 |
| 18802726 | METHODS FOR OBTAINING STERILE MILK AND COMPOSITIONS THEREOF | MORNHINWEG, JEFFREY P | — | §103 | Final Rejection | — | Pending | Aug 13, 2024 |
| 18659554 | HUMAN MILK PRODUCTS USEFUL IN PRE- AND POST-OPERATIVE CARE | KOSAR, AARON J | 1655 | DP | Non-Final OA | — | Pending | May 09, 2024 |
| 18406627 | PURIFIED HUMAN MILK OLIGOSACCHARIDES COMPOSITIONS | HAWKINS, AMANDA SALATA | 1793 | §102§103§112 | Non-Final OA | — | Pending | Jan 08, 2024 |
| 18552081 | METHODS OF TREATMENT FOR FAILURE TO THRIVE | FIEBIG, RUSSELL G | 1655 | §102§103Other | Final Rejection | — | Pending | Sep 22, 2023 |
| 18261012 | SYNBIOTIC TREATMENT REGIMENS | OLSON, ANDREA STEFFEL | 1693 | §102§103Other | Final Rejection | 96d overdue | Pending | Jul 11, 2023 |
| 18021043 | HUMAN MILK OLIGOSACCHARIDE COMPOSITIONS FOR USE WITH BACTERIOTHERAPIES | MILLER, DALE R | 1693 | §103DP | Non-Final OA | — | Pending | Feb 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial